Please login to the form below

Not currently logged in
Email:
Password:

gene therapy

This page shows the latest gene therapy news and features for those working in and with pharma, biotech and healthcare.

GSK hands rare disease assets over to Orchard

GSK hands rare disease assets over to Orchard

At the time, chief executive Emma Walmsley said the rare diseases unit - which chalked up one success with the launch of ex vivo gene therapy Strimvelis for children with adenosine deaminase ... GSK isn’t exiting cell and gene therapy entirely, as it

Latest news

More from news
Approximately 13 fully matching, plus 121 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    Standing ready. If all goes to plan, gene therapy, a loose umbrella term for modalities that alter genes to treat or prevent disease, stands at the threshold of enormous clinical success. ... But wait, there’s more: well established and respected

  • The rise of real-world evidence The rise of real-world evidence

    Novartis secured such an outcome-based model for its CAR-T therapy Kymriah. ... Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.

  • A unique ecosystem A unique ecosystem

    Regenerative medicine aims to repair injuries or diseased organs using biomaterials, gene therapy, cell therapy and tissue engineering.

  • Gene therapy Gene therapy

    How are these limitations impacting current gene therapy programmes? What is the roadblock to gene therapy? ... the promise of gene therapy in the early nineties could not be remotely met.

  • Pharma deals continue to slide Pharma deals continue to slide

    Gilead seems to have got its timing right because two days after the announcement of the acquisition the FDA announced “a historic action today making the first gene therapy available in ... 425 (upfront 80). Calimmune (US). CSL (AU). Company

More from intelligence
Approximately 3 fully matching, plus 29 partially matching documents found.

Latest appointments

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    been able to go for over a year with no additional myeloma therapy and tolerable adverse effects.”. ... well as a pipeline of other cell and gene therapy candidates.

  • Gyroscope Therapeutics appoints CEO Gyroscope Therapeutics appoints CEO

    Dr Bekkali’s previous leadership positions include global head of the ophthalmology business unit at Sanofi, where she led its ophthalmology strategy towards ocular gene therapy and set up a multidisciplinary ... team. Chris Hollowood, chairman of the

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    Voyager Therapeutics appoints Matthew Ottmer as chief operating officer. He joins the gene therapy group from Momenta Pharmaceuticals. ... Gene therapy focused group Voyager Therapeutics has appointed Matthew Ottmer as its new chief operating officer.

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    He said: “Now is an exciting time to be joining Orchard as the cell and gene therapy field is advancing successfully. ... The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and

  • Anne Prener to lead Freeline Therapeutics Anne Prener to lead Freeline Therapeutics

    London, UK-based gene therapy-focused biopharmaceutical company Freeline Therapeutics has appointed Anne Prener as its new chief executive officer. ... She joins from Gyroscope Therapeutics where she was CEO and brings to her new role experience in drug

More from appointments
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest from PMHub

  • Will gene therapies finally be commercially viable to pharma?

    Will gene therapies finally be commercially viable to pharma? Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of ... We review gene therapy’ s chequered past, look at recent

  • Innovation in pharma: the highs and lows of the current healthcare economy

    Gene therapies often require a ‘ one-time only’ treatment offering life-changing potential to patients with conditions where currently there may be no available therapy at all, for instance, in rare ... Also in cancers: chimeric antigen receptor T

  • Healthcare in the Digital Age

    Exciting developments in immunotherapy and oncology, and huge strides in gene and stem-cell therapy are matched by powerhouse collaborations between academia and industry that point to a golden age for

  • PAN trio run for charity

    RP Fighting Blindness is funding pioneering gene therapy research at Moorfields Eye Hospital which represents one of the best opportunities for a breakthrough in treatment of RP. ... We should be able to make a really significant contribution to the gene

  • SEVEN STONES

    Branding. Digital and tech solutions. Exercise co-prescription. Workplace wellbeing. Experience. Anti-infectives, cardiovascular, contrast media, dermatology, diabetes, diagnostics, gastroenterology, gene therapy, health and fitness, hepatology,

More from PMHub
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics